A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/28/2002	CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002	CA2447918A1 Method of treating dry eye disorders
11/28/2002	CA2447883A1 Use of nf-kappa-b inhibitors to treat dry eye disorders
11/28/2002	CA2447793A1 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	CA2447780A1 Process for the production of 6, 7 - dihydroxy steroid compounds by allylic oxidation of steroid - 5 - ene compounds to steroid - 5 - ene - 7 - one compounds followed by hydroboration and oxidation and intermediates of this process
11/28/2002	CA2447716A1 Preventive or remedy for diseases caused by cerebrovascular disturbances
11/28/2002	CA2447676A1 New benzylaminopyrimidines
11/28/2002	CA2447675A1 Novel pyridylmethylaminopyrimidines
11/28/2002	CA2447671A1 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002	CA2447619A1 A composition for accelerating bone fracture healing
11/28/2002	CA2447618A1 A composition for regenerative treatment of cartilage disease
11/28/2002	CA2447603A1 Granular preparations of gaboxadol
11/28/2002	CA2447600A1 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
11/28/2002	CA2447598A1 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
11/28/2002	CA2447465A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain
11/28/2002	CA2447233A1 Process for the production of quinazolines
11/28/2002	CA2447231A1 Methods for inhibiting angiogenesis
11/28/2002	CA2447227A1 Process for the preparation of imipenem
11/28/2002	CA2447161A1 Conjugates and compositions for cellular delivery
11/28/2002	CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002	CA2447066A1 Method of treatment for cancers associated with elevated
11/28/2002	CA2447063A1 Novel use
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002	CA2446801A1 Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
11/28/2002	CA2446620A1 Antiviral nucleosides
11/28/2002	CA2446516A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446510A1 Therapeutic agent for tumor of neural origin
11/28/2002	CA2446332A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446331A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446324A1 Quinoline derivatives as ligands for the neuropeptide y receptor
11/28/2002	CA2446316A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446313A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446311A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446155A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002	CA2446154A1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2445789A1 Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
11/28/2002	CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2445010A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002	CA2444787A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
11/28/2002	CA2444487A1 Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists
11/28/2002	CA2443438A1 Cytotoxic cd44 antibody immunoconjugates
11/28/2002	CA2443437A1 Antibodies specific for cd44v6
11/28/2002	CA2443287A1 Methods for regulating bacteria
11/28/2002	CA2443068A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/28/2002	CA2427619A1 Pharmaceutically active isoindoline derivatives
11/28/2002	CA2410763A1 Medicinal compositions containing propenone derivatives
11/28/2002	CA2410628A1 Carbamic acid esters
11/28/2002	CA2410627A1 Glycinamides
11/28/2002	CA2349123A1 Anionic exchange polymer complexes of buspirone
11/27/2002	EP1260519A1 Membrane receptors for steroids and sterols
11/27/2002	EP1260512A1 Novel cyclic amide derivatives
11/27/2002	EP1260509A1 Uses of tocopherol esters
11/27/2002	EP1260504A1 Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
11/27/2002	EP1260502A1 Vitamin d derivatives having substituents at the 2alpha-position
11/27/2002	EP1260233A1 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
11/27/2002	EP1260232A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
11/27/2002	EP1260228A2 Human growth gene and short stature gene region. Therapeutic uses
11/27/2002	EP1260227A1 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
11/27/2002	EP1260225A1 A pharmaceutical composition for use in hormone replacement therapy
11/27/2002	EP1260224A1 Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage
11/27/2002	EP1260223A1 Taxanes having furyl or thienyl substituted side-chain
11/27/2002	EP1260222A1 Butenyl-substituted taxanes and composition
11/27/2002	EP1260221A2 Combination treatment for depression and anxiety
11/27/2002	EP1260215A1 Rapidly disintegrable tablet containing polyvinyl alcohol
11/27/2002	EP1260212A1 Cosmetic composition
11/27/2002	EP1260211A1 Skin preparations for external use
11/27/2002	EP1260210A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same
11/27/2002	EP1259923A2 Anti-infective agents useful against mulitidrug-resistant strains of bacteria
11/27/2002	EP1259813A2 Diagnosis and treatment of malignant neoplasms
11/27/2002	EP1259812A2 Breast, gastric and prostate cancer associated antigens and uses therefor
11/27/2002	EP1259648A2 Diagnostics and therapeutics for glaucoma
11/27/2002	EP1259638A2 Methods for selectively modulating survivin apoptosis pathways
11/27/2002	EP1259637A2 Caspase-inhibitory-factor (cif) and uses thereof
11/27/2002	EP1259622A2 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method
11/27/2002	EP1259605A2 Mutated cyclin g1 protein
11/27/2002	EP1259604A1 Bcmp 84, a protein associated to breast cancer
11/27/2002	EP1259603A2 Antisense oligonucleotides of the human chk1 gene and uses thereof
11/27/2002	EP1259550A1 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
11/27/2002	EP1259527A1 35 human secreted proteins
11/27/2002	EP1259523A2 Pluraflavins and derivatives thereof, process for their preparation and use thereof
11/27/2002	EP1259520A2 Novel purines
11/27/2002	EP1259515A2 Thienopyridine derivatives and their use as anti-inflammatory agents
11/27/2002	EP1259514A2 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
11/27/2002	EP1259513A2 A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
11/27/2002	EP1259512A1 Pteridine compounds for the treatment of psoriasis
11/27/2002	EP1259510A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
11/27/2002	EP1259508A1 Novel biarylcarboxamides
11/27/2002	EP1259507A1 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
11/27/2002	EP1259506A1 Pyrazinone thrombin inhibitors
11/27/2002	EP1259505A2 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
11/27/2002	EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002	EP1259502A2 Biologically active analogs of discodermolide
11/27/2002	EP1259501A2 Method for the preparation of citalopram
11/27/2002	EP1259500A1 Method for the preparation of citalopram
11/27/2002	EP1259499A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
11/27/2002	EP1259498A1 8,8a-dihydro-indeno 1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents
11/27/2002	EP1259497A1 Novel quinoline ligands and metal complexes for diagnosis and therapy
11/27/2002	EP1259495A2 Indane derivatives and their use as cell adhesion inhibitors

1 ... 5638 5639 5640 5641 5642 5643 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 ... 7860